As I’ve written in prior blogs, the EU General Data Protection Regulation (GDPR) is going to impose significant privacy and security requirements on U.S. companies that might fall within its reach. I was recently interviewed by Allison Proffitt, an editor and reporter for several health related publications.

One of the significant implications that I raised with her is the GDPR’s impact on U.S. based clinical trials. She quoted me at length in her recent article about this very issue. Her October 24th article is titled “What Europe’s New Privacy Regulations Mean for US Trials” and can be found at clinicalinformaticnews.com.